Latest Partnerships News

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Kincora Copper says 2026 drilling has identified multiple porphyry-style intrusive complexes across its Nevertire and Nevertire South licences, expanding the interpreted prospective strike beyond 40 kilometres. The results remain early-stage, but AngloGold Ashanti’s potential A$100 million earn-in gives the exploration program meaningful financial backing.

Apollo Minerals has completed a 180-line-kilometre airborne magnetic and radiometric survey over its Couflens tungsten-gold project in France, with the work conducted alongside the French Geological Survey. The data is still being processed, but it could help shape the next phase of exploration, including planned underground drilling at the Véronique zone.

Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.

Kali Metals has secured up to $700,000 in exploration funding from Japan’s JX Advanced Metals for its 1,413 square kilometre Southern Lachlan project. The agreement creates a pathway to a potential farm-in or joint venture, but no formal deal has yet been agreed.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Enterprise Metals has secured $1.2 million in discounted equity funding alongside a proposed board overhaul led by mining executives Phillip Gallagher and Steven Zaninovich. The incoming team will review the company’s Western Australian portfolio and decide where its limited exploration capital should go next.

X2M Connect has signed a non-binding two-year MOU with Gateway DC covering data centre development, delivery and platform deployment across Australia and potentially Southeast Asia. The opportunity links Gateway’s planned 120MW-to-2GW-plus Darwin roadmap with X2M’s prospective pipeline exceeding 200MW, but revenue remains subject to future binding agreements.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Everest Metals moved Mt Dimer into mining, established a 260,780-ounce Revere gold resource and upgraded its Mt Edon rubidium project in FY2026. Yet the company remains loss-making, has impaired its Mt Dimer development assets and warns that future funding and project cash inflows are needed to support its going-concern assessment.

Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.

AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.